Retrospective Analyses of PD-L1, LAG-3, TIM-3, OX40L Expressions and MSI Status in Gastroenteropancreatic Neuroendocrine Neoplasms

被引：0

作者：

Gurler, Fatih ^{[1
,8
]}

Esen, Selin Akturk ^{[2
]}

Inci, Bediz Kurt ^{[3
]}

Sutcuoglu, Osman ^{[4
]}

Ucar, Gokhan ^{[2
]}

Akdogan, Orhun ^{[5
]}

Uncu, Dogan ^{[2
]}

Turhan, Nesrin ^{[6
]}

Akyurek, Nalan ^{[7
]}

Ozdemir, Nuriye ^{[4
]}

Ozet, Ahmet ^{[4
]}

Yazici, Ozan ^{[4
]}

机构：

[1] Univ Hlth Sci, Dr Abdurrahman Yurtaslan Oncol Training & Res Hosp, Dept Med Oncol, Ankara, Turkiye

[2] Univ Hlth Sci, Ankara City Hosp, Dept Med Oncol, Ankara, Turkiye

[3] Aksaray Training & Res Hosp, Dept Med Oncol, Aksaray, Turkiye

[4] Gazi Univ, Sch Med, Dept Med Oncol, Ankara, Turkiye

[5] Yenimahalle Training & Res Hosp, Dept Internal Med, Ankara, Turkiye

[6] Univ Hlth Sci, Ankara City Hosp, Dept Pathol, Ankara, Turkiye

[7] Gazi Univ, Sch Med, Dept Pathol, Ankara, Turkiye

[8] Univ Hlth Sci, Dr Abdurrahman Yurtaslan Oncol Training & Res Hosp, Dept Med Oncol, Yenimahalle Ankara, Turkiye

来源：

CANCER INVESTIGATION | 2024年 / 42卷 / 02期

关键词：

PD-L1; LAG-3; TIM-3; OX40L; MSI; TUMOR-INFILTRATING LYMPHOCYTES; MICROSATELLITE INSTABILITY; PHASE-II; CANCER; PATHWAYS; EFFICACY; PROTEIN; SAFETY; CD223;

D O I：

10.1080/07357907.2024.2330102

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We investigated expressions of PD-L1, LAG-3, TIM-3, and OX40L as immune checkpoint proteins, and MSI (repetitive short-DNA-sequences due to defective DNA-repair system) status were analyzed with immunohistochemistry from tissue blocks. Of 83 patients, PD-L1 expression was observed in 18.1% (n = 15) of the patients. None of the patients exhibited LAG-3 expression. TIM-3 expression was 4.9% (n = 4), OX40L was 22.9% (n = 19), and 8.4% (n = 7) of the patients had MSI tumor. A low-to-intermediate positive correlation was observed between PD-L1 and TIM-3 expressions (rho: 0.333, p < 0.01). Although PD-L1 expression was higher in grade 3 NET/NEC, MSI status was prominent in grade 1/2 NET.

引用

页码：141 / 154

页数：14

共 50 条

[21] Triple-Negative Breast Cancer: Intact Mismatch Repair and Partial Co-Expression of PD-L1 and LAG-3 [J].

Wu, Shafei ;

Shi, Xiaohua ;

Wang, Jing ;

Wang, Xuefei ;

Liu, Yuanyuan ;

Luo, Yufeng ;

Mao, Feng ;

Zeng, Xuan .

FRONTIERS IN IMMUNOLOGY, 2021, 12

[22] Enhanced antitumor efficacy of bispecific antibody blocking PD-L1 and LAG-3 with doxorubicin: mechanism and safety evaluation [J].

Zhang, Chenxing ;

Liu, Jiaxin ;

Gu, Tiejun ;

Meng, Xiangyu ;

Cai, Xiaoyi ;

Zhang, Jinfeng ;

Chen, Yan ;

Zhang, Daguang ;

Wu, Yongge .

BREAST CANCER RESEARCH AND TREATMENT, 2025, 211 (03) :637-648

[23] Characteristics and clinical correlation of TIM-3 and PD-1/PD-L1 expressions in leukemic cells and tumor microenvironment in newly diagnosed acute myeloid leukemia [J].

Chajuwan, Thunyamon ;

Kansuwan, Patsita ;

Kobbuaklee, Sirorat ;

Chanswangphuwana, Chantiya .

LEUKEMIA & LYMPHOMA, 2022, 63 (02) :450-456

[24] Small molecule inhibitors targeting PD-L1, CTLA4, VISTA, TIM-3, and LAG3 for cancer immunotherapy (2020-2024) [J].

Cheng, Binbin ;

Lv, Jinke ;

Xiao, Yao ;

Song, Changshan ;

Chen, Jianjun ;

Shao, Chuxiao .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2025, 283

[25] LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes [J].

He, Yayi ;

Yu, Hui ;

Rozeboom, Leslie ;

Rivard, Christopher J. ;

Ellison, Kim ;

Dziadziuszko, Rafal ;

Suda, Kenichi ;

Ren, Shengxiang ;

Wu, Chunyan ;

Hou, Likun ;

Zhou, Caicun ;

Hirsch, Fred R. .

JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (05) :814-823

[26] DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer [J].

Nair, Varun Sasidharan ;

El Salhat, Haytham ;

Taha, Rowaida Z. ;

John, Anne ;

Ali, Bassam R. ;

Elkord, Eyad .

CLINICAL EPIGENETICS, 2018, 10

[27] DNA methylation and repressive H3K9 and H3K27 trimethylation in the promoter regions of PD-1, CTLA-4, TIM-3, LAG-3, TIGIT, and PD-L1 genes in human primary breast cancer [J].

Varun Sasidharan Nair ;

Haytham El Salhat ;

Rowaida Z. Taha ;

Anne John ;

Bassam R. Ali ;

Eyad Elkord .

Clinical Epigenetics, 2018, 10

[28] Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration [J].

Oweida, Ayman ;

Hararah, Mohammad K. ;

Phan, Andy ;

Binder, David ;

Bhatia, Shilpa ;

Lennon, Shelby ;

Bukkapatnam, Sanjana ;

Van Court, Benjamin ;

Uyanga, Nomin ;

Darragh, Laurel ;

Kim, Hyun Min ;

Raben, David ;

Tan, Aik Choon ;

Heasley, Lynn ;

Clambey, Eric ;

Nemenoff, Raphael ;

Karam, Sana D. .

CLINICAL CANCER RESEARCH, 2018, 24 (21) :5368-5380

[29] PD-1、PD-L1、TIM-3在口腔鳞癌中的表达及临床意义 [J].

史慧洁 ;

李俊冉 ;

闫秋杰 ;

杨超 ;

张媛媛 .

河南医学研究, 2019, 28 (11) :1924-1926

[30] Impact of the combination of sintilimab and chemotherapy on the tumor and paratumor PD-L1, IDO, TIM-3, FOXP3+and CD8 expressions in patients with advanced esophageal squamous cell carcinoma [J].

Zhang, Shifa ;

Cai, Haibo ;

Huang, Junjun ;

Wang, Gongchao .

THORACIC CANCER, 2022, 13 (23) :3284-3294

← 1 2 3 4 5 →